Affinia receives FDA fast track designation for AFTX-201
Affinia Therapeutics has officially received the US Food and Drug Administration (FDA) fast track designation (FTD) for its lead candidate, AFTX-201. This genetic medicine is currently under investigation for the treatment of Bcl-2-associated athanogene 3 (BAG3)-associated dilated cardiomyopathy (DCM), a serious condition that significantly impacts cardiac function.
[Image of dilated cardiomyopathy pathophysiology]Innovative Cardiac Transduction Capsid
AFTX-201 is being evaluated as a one-time intravenous gene therapy in adults with genetically confirmed BAG3 DCM. The therapy delivers a fully human, full-length BAG3 transgene using the company’s proprietary capsid, which is specifically engineered for cardiac transduction.
One of the critical advantages of this technology is its potency: it operates at doses five to ten times lower than traditional gene therapies like AAV9 or AAVrh74. Currently, the therapy is undergoing assessment in the Phase I/II UPBEAT clinical trial.
Trial Overview: Phase I/II UPBEAT Clinical Study
- Design: Single-arm, open-label, multi-centre trial evaluating pharmacodynamics, safety, and preliminary efficacy.
- Structure: Comprises both dose-exploration and dose-expansion phases.
- Protocol: All participants receive a single intravenous infusion supported by preclinical proof-of-concept findings.
- Monitoring: 52-week post-administration safety monitoring with additional oversight from an independent Data Safety Monitoring Board.
“We are grateful to the FDA for granting the fast track designation to AFTX-201 and to the patient and physician communities for their support of our UPBEAT clinical trial. This designation, together with the FDA’s recent IND approval and the EMA’s orphan drug designation, strengthens our conviction that AFTX-201 has the potential to significantly improve the lives of those affected by BAG3 DCM.”
Hideo Makimura, M.D., Ph.D., Chief Medical Officer of Affinia TherapeuticsAccelerating the Path to Market
The Fast Track Designation is designed to facilitate the development and expedite the review of drugs intended to treat serious conditions and address unmet medical needs. Programs granted FTD benefit from early and frequent interaction with the FDA. Furthermore, companies may submit marketing applications on a rolling basis, meaning the FDA can review sections of the application before the entire document is finished.
If specific criteria are met, AFTX-201 could also be eligible for accelerated approval or priority review, which could significantly reduce the time required to bring this life-saving therapy to patients.
This regulatory milestone follows a successful period for the company. In October 2025, Affinia Therapeutics raised $40m in a Series C funding round, led by New Enterprise Associates, providing the financial foundation to advance its cardiac gene therapy pipeline.
